Intensification of glucose-lowering treatment in patients with diabetes mellitus type 2 on insulin therapy: Perspectives of dapagliflozin

Código QR

Intensification of glucose-lowering treatment in patients with diabetes mellitus type 2 on insulin therapy: Perspectives of dapagliflozin

Intensification of antihyperglycaemic treatment in patients with poorly controlled type 2 diabetes mellitus who were on insulin therapy remains a difficult issue. Results from clinical trials with the sodium-glucose linked transporter (SGLT-2) inhibitor dapagliflozin as add-on therapy in patients wi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Olga Yuryevna Sukhareva, Marina Vladimirovna Shestakova
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2016
Materias:	diabetes mellitus type 2 insulin therapy sglt-2 inhibitor dapagliflozin Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/e17f2caabd3249238ccbbc7061e11d02
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin
por: Avgerinos I, et al.
Publicado: (2019)

When basal insulin is not enough: successful strategies for insulin intensification in patients with type 2 diabetes mellitus
por: Elena V. Buryukova, et al.
Publicado: (2017)

Can simple intensification of therapy with modern two-phase insulin help in type 2 diabetes when target glycemia failed to be achieved withbasal insulin? Results of subanalysis in the PRESENT study
por: Ch S Yang, et al.
Publicado: (2009)

Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction – a practical approach
por: Jadwiga Nessler
Publicado: (2021)

Patient considerations in type 2 diabetes – role of combination dapagliflozin–metformin XR
por: Kuecker CM, et al.
Publicado: (2016)

Individual stepwise intensification of insulin analogue therapy in type 2 diabetes mellitus
por: Alexander Sergeevich Ametov, et al.
Publicado: (2012)

Glycemia control and glucose-lowering therapy in patients with type 2 diabetes mellitus and cardiovascular disease (review of multicenter randomized trials)
por: Sergey V. Kakorin, et al.
Publicado: (2016)

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
por: Simes BC, et al.
Publicado: (2019)

A1chieve Program in Russian Federation: a multicenter prospective observational study of insulin analogue treatment efficiency and safety in daily management of patients with type 2 diabetes mellitus, who startand intensify insulin treatment having never received it before
por: Marina Vladimirovna Shestakova
Publicado: (2012)

Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy
por: Gagik Radikovich Galstyan, et al.
Publicado: (2015)

Therapy with biphasic insulin aspart 30/70 (NovoMix 30) improves glycemic control in patients with type 2 diabetes mellitus: resultsfrom a Russian cohort of IMPROVE observational program designed to study safety and efficiency of biphasic insulin aspart 30 inroutine clinical practice
por: Marina Vladimirovna Shestakova, et al.
Publicado: (2010)

Effects of metformin on body weight in patients with type 2 diabetes mellitus,receiving insulin analogue treatment
por: Tatiana Ivanovna Romantsova, et al.
Publicado: (2013)

Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents
por: Stefan D. Anker
Publicado: (2019)

Sodium-Glucose Cotransporter-2 Inhibitors Improve Cardiovascular Dysfunction in Type 2 Diabetic East Asians
por: Muhammad Afzal, et al.
Publicado: (2021)

Basal insulin therapy in patients with type 2 diabetes mellitus and poor control of glycemia by oral hypoglycemic agents: results of direct comparative study of insulin analogs Lantus and Levemir
por: Alsu Gafurovna Zalevskaya, et al.
Publicado: (2010)

Efficacy and safety of treatment with human insulin analogues in daily management of insulin naive patients with type 2 diabetes mellitus: results of multicenter 52-week observational study A1chive
por: Marina Vladimirovna Shestakova
Publicado: (2012)

Early insulin therapy Coordination Council
por: Marina Vladimirovna Shestakova
Publicado: (2012)

The effects of structured self-monitoring of blood glucose on therapeutic effectiveness and adherence in patients with type 2 diabetes mellitus initiating insulin treatment
por: Lyudmila Alexandrovna Suvorova, et al.
Publicado: (2013)

Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program
por: Marina Vladimirovna Shestakova
Publicado: (2010)

DECLARE-TIMI 58 trial in the context of EMPA-REG OUTCOME and CANVAS
por: Marina V. Shestakova
Publicado: (2019)

Overcoming marked insulin resistance in a patient with type 2 diabetes mellitus by means of insulin pumptherapy
por: Ekaterina Viktorovna Artemova, et al.
Publicado: (2012)

Comparative efficacy assessment for various insulin regimens in patients with type 2 diabetes mellitus, ischaemic heart disease and frequent hypoglycemic events
por: Vladimir Ivanovich Kudinov, et al.
Publicado: (2012)

A review of insulin lispro for the treatment of patients with type 2 diabetes mellitus
por: Marina V. Shestakova, et al.
Publicado: (2016)

Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
por: Ivan Ivanovich Dedov, et al.
Publicado: (2014)

Second line therapy in type 2 diabetes: legacy effect activation
por: Ekaterina A. Shestakova
Publicado: (2017)

Selected aspects of insulin pump therapy and continuous glucose monitoring in real time (in relation to the letter of E.D.Gorbachev)
por: Yury Ivanovich Filippov, et al.
Publicado: (2010)

Glucose-lowering therapies in patients with diabetes mellitus and chronic kidney disease
por: Minara Shamkhalovna Shamkhalova, et al.
Publicado: (2013)

Hypoglycemia in type 2 diabetes patients treated with insulin: the advantages of continuous glucose monitoring
por: Vadim Valer'evich Klimontov, et al.
Publicado: (2014)

Insulin degludec is a new ultra-long-acting insulin analogue
por: Ivan Ivanovich Dedov, et al.
Publicado: (2014)

Modern approach to basal-bolus therapy with glargine and glulisine insulin analoguesin various age groups
por: Natalya Nikitichna Volevodz, et al.
Publicado: (2013)

Actual ambulatory care in patients with type 2 diabetes mellitus in Russian Federation according to open label prospectiveobservational study DIA-CONTROL
por: Marina Vladimirovna Shestakova
Publicado: (2011)

Russian Association of Endocrinologists expert consensus document on initiation and intensification of antyhyperglycaemic therapyin type 2 diabetes mellitus
por: Ivan Ivanovich Dedov, et al.
Publicado: (2011)

Is cancer incidence modified by SGLT2 inhibitors?
por: Lev M. Berstein
Publicado: (2019)

Empagliflozin: a new strategy for nephroprotection in diabetes
por: Anton Ivanovich Korbut, et al.
Publicado: (2017)

Modern antihyperglycemic agents prescribed in Russia for type 2 diabetes mellitus
por: Yury Ivanovich Suntsov
Publicado: (2012)

Heart failure in diabetes: From an increased risk to a treatment target
por: Eberhard Standl
Publicado: (2018)

Diabetes mellitus associated with the mutation of the ABCC8 gene (MODY 12): features of clinical course and therapy
por: Alla K. Ovsyannikova, et al.
Publicado: (2019)

Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin
por: Yu H, et al.
Publicado: (2017)

Control of type 2 diabetes mellitus: problems and prospects for their solution
por: Tatiana Ivanovna Romantsova, et al.
Publicado: (2009)

Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus
por: Ahmadieh H, et al.
Publicado: (2017)